Peptides can affect the recognition of MHC class I molecules by allospecific antibodies. Two explanations have been proposed for this phenomenon. The 'conformatlonal change' hypothesis suggests that peptide binding affects the availability of serologic determinants In the class I <x1 and <x2 domains while the 'peptlde-side-chain effect' predicts that solvent exposed residues in the peptide are part of the serologic epitope. We 
Introduction
MHC class I molecules function as peptide receptors that bind proteolytic products of intracellular antigens and present them at the cell surface for recognition by cytotoxic T lymphocytes (CTL) (1). The molecule consists of a highly polymorphic heavy chain and non-covalently attached light chains. The crystal structure of several class l-peptide complexes has shown that the peptide binding site is formed by the heavy chain and is composed of an eight stranded antiparallel p-sheet and two a-helices that constitute the floor and the walls respectively of the binding cleft (2). A set of conserved residues at both ends of the binding cleft serves to chelate the charged termini of the peptide while the majority of polymorphism in class I molecules is located within the cleft and is concentrated in a series of pockets which accommodate the amino acid side chains of the peptide, determining the specificity of binding (3) . Thus, while peptides binding to a given class I allele tend to be of a defined length and share similar anchor residues that are buried in the pockets of the binding cleft (4) (5) (6) , the remaining highly variable residues arch away from the floor of the groove, exposing several of their side chains to the solvent. The exposed portion of the peptide can contact the TCR, determining, with its variability, the antigenic character of the class I complex.
In addition to determining the specificity of the TCR contact site, peptides were shown to influence the reactivity of certain antibodies against class I and II MHC complexes. This was clearly demonstrated by the differential staining of transporters associated with antigen processing (TAP)-deficient mouse or human cells pulsed with peptides derived from cellular or viral antigens (7) (8) (9) (10) (11) , by the selective immunoprecipitation of complexes containing different peptide pools (12) and by the positive or negative influence of the bound peptide on the recognition of soluble class I molecules refolded in vitro (13) . Two, perhaps nonmutually exclusive, explanations have been proposed for this phenomenon. One is that the binding of certain peptides influences the exposure of the conformational epitope of the MHC heavy chain itself. Although crystallographic studies suggest that the conformation of the class I molecule is largely unaltered by peptide sequence variation, reorientation of a few amino acid side chains and subtle local shifts in the main chains of the a-helices were indeed observed (14) . Evidence in favour of this interpretation came from the finding that binding of peptides lacking the consensus L d anchor residue of Pro at position 2 impaired serologic recognition by the B22/249 antibody (15) . Furthermore, other peptides rescued the recognition of L d molecules that carry mutations within the peptide binding cleft or at sites that may affect interaction with p 2 -microglobulin (&$r\) (16) . An alternative explanation suggests that residues within the peptide may shape the antibody binding site either directly or by obscuring the residues with which the antibody interacts. This explanation is mainly supported by studies where peptide mutants were compared for their ability to influence antibody recognition. Thus, in many cases, variants at solvent exposed positions were shown to prevent antibody binding and, in general, the bulkier the side chain, the greater the inhibitory effect (8, 9) .
In the present investigation we have used a multidisciplinary approach to investigate the recognition of HLA A*1101 molecules carrying different peptides by allospecific mAb and by peptide-specific CTL. The purpose of this analysis was to define the primary MHC contact residues within the peptide by orienting the peptide in the A11 groove, and to compare the effect of substitutions at putative solventexposed residues on the recognition of the complexes by specific TCR and by All-specific antibodies that react in a peptide-dependent fashion. Two possible conformations of A11 molecules complexed with the 9-mer peptide IVTDFSVIK from the Epstein-Barr virus (EBV) nuclear antigen (EBNA)-4 are predicted by the effect of Ala scanning mutagenesis on the reactivity of specific CTL clones while the 10-mer peptide AVFDRKSDAK appears to assume a more rigid conformation. A striking similarity was observed in the effect of Ala scanning mutagenesis on serologic reactivity and triggering of CTL responses raising the possibility that a similar binding surface may be recognized by antibodies and TCR.
Methods

Cell lines
The T2/A11 and BM36.1/A11 cell lines, obtained by transfection of the peptide processing mutant T2 (17) and BM36.1 (18) cell lines with a pHEBO vector based HLA A* 1101 expression vector (19) , were maintained in medium containing 200 \ig/m\ hygromycin-B. EBV-transformed lymphoblastoid cell lines (LCL) were established by infection of blood B lymphocytes from HLA class I type donors with spent supernatant from the virus produced B95.8 cell line (20) .
Synthetic peptides
Peptides, synthesized by the Merrifield solid phase method (21) , were purchased from Alta Bioscience (The University of Birmingham, Birmingham, UK). The peptides were dissolved in DMSO at a concentration of 10~2 M and further diluted in PBS to obtain the indicated concentrations before use. The protein concentration of the DMSO stock solutions was determined by a Biuret assay (22 (31) . Ala mutagenesis scanning of the IVT and AVF peptides was performed using synthetic analogues where each residue was sequentially substituted by Ala. The analogues are identified by the amino acid in single letter code followed by a number indicating the position in the wild-type peptide.
Antibodies
Culture supernatants from the mouse hybridomas W6/32 (32), AUF5.13 (33) and HB164 (34) , and the human hybridoma Trj14 (35) were used to detected HLA A*1101 molecules in indirect immunofluorescence assays. The W6/32 mAb recognizes a monomorphic determinant on all HLA class l-p2m complexes while AUF5.13 recognizes polymorphic determinants shared by HLA A*1101 and A3, and HB164 recognizes determinants shared by HLA A*1101 and A24. The Trj14 mAb was shown to react broadly with several HLA A alleles including A2, A3, A11, A30, A31, A22, Aw68 and Aw69.
Detection of HLA A'1101-peptide complexes
Surface class I antigen expression was detected in BM36.1/ A11 after overnight culture at 37°C in AIM-V serum-free medium (Gibco) with or without addition of the indicated peptide at a final concentration of 100 ^M. After extensive washing in peptide-free PBS, the cells were incubated with the specific mAb for 30 min at 4°C, washed two times in PBS and further incubated for 30 min at 4°C with FITC-conjugated rabbit anti-mouse Ig or rabbit anti-human IgG F(ab') 2 fragment. Surface class I molecules were detected with a FACScan flow cytometer (Becton Dickinson, Mountain View, CA). Fluorescence histograms were made by logarithmic amplification of fluorescence emitted by 5000 viable cells. Statistical analyses were performed with the CellQuest computer software.
Peptide-induced refolding of surface A11 molecules
Temperature-sensitive class I molecules that are either 'empty' or contain low-affinity binding peptides (36) were induced by overnight incubation of 2X10 7 T2/A11 cells in 40 ml AIM-V medium at 26°C and the unstable complexes were destroyed by incubation for 2 min at pH 3 in 5 ml citrate-phosphate buffer containing 0.131 M citric acid and 0.063 M Na 2 HPO 4 (37) . After washing in PBS to restore physiological pH, aliquots of 2x 10 6 cells were incubated for 2 h at 4°C in PBS containing 100 mM of the indicated peptides and 1.5 (j.g/ml human f^m (Sigma). Surface HLA A*1101 expression was detected by FACS analysis of cells stained with the W6/32 and AUF5.13 mAb.
Generation of CTL clones and cytotoxicity assays
EBV-specif ic CTL were obtained by stimulation of lymphocytes from the EBV seropositive donor BK (HLA A2.11 B7.62) with the autologous B95.8 virus-transformed LCL as previously described (38) . After two or three consecutive re-stimulations the cultures were expanded in complete medium supplemented with 10 U/ml recombinant IL-2 and 30% (v/v) culture supernatant from the gibbon lymphoma line MLA144 (39) . Single cell cloning was done by limiting dilution in medium containing 30% MLA144 culture supernatant, 10 U/ml human recombinant IL-2 and 10 5 irradiated (3000 rad) allogeneic phytohaemagglutinin (PHA)-activated peripheral blood lymphocytes as feeder. Growing cultures were transferred into 48-well plates and were fed twice a week by replacing half of the medium. The EBV specificity and HLA class I restriction of the CTL preparations was investigated by testing their cytotoxic activity against a panel of EBV-positive and -negative targets including the autologous LCL, allogeneic LCL-matched through single HLA class I alleles, at least two cell lines for each allele, PHA-activated blasts, HLAmismatched LCL and the prototype NK-sensitive target K562. Cytotoxic activity was measured in standard 5 h 51 Cr-release assays at 10:1, 3:1 and 1:1 effector:target ratios in triplicate (38) . The targets were labelled with Na 51 Cr0 4 (0.1 nCi/10 6 cells) for 1 h at 37°C. Recognition of the EBNA4 peptides and their Ala mutated analogues was tested using as targets HLA A* 1101-positive blasts that had been preincubated with 10" 8 M of the peptide during labelling.
Molecular modelling of the complexes between HLA-A'1101 and the AVF and IVT peptides
Model building was carried out using the program O (40) and all models were subjected to energy minimization using the program XPLOR (41) . The same program was used to test the stability of the resulting complexes by subjecting them to 100 ps of dynamics in 0.001 ps time steps while keeping the temperature constant. The model of HLA A*1101 was built based on the crystal structure of HLA A*0201 (2) to which it has 92.6% identical amino acids. The models of the IVT peptide were based on the crystal structures of six 9-mer peptides (Table 2) bound to HLA A*0201 (14) (Brookhaven Protein Data Bank entries 1hhi, 1hhj, 1hhg, 1hhk), H-2D b (42) (1hoc) and H-2K b (43) (1vab). Inspection of these structures showed that the side chains of residues at P1 to P4 and P7 to P9 maintain a fairly conserved orientation relative to the binding cleft while the side chains of P5 and P6 may either point 'up' away from the cleft or 'down' into the groove. A model with a conformation of the IVT peptide with the side chain of Phe-P5 pointing 'down' was not possible to build due to steric hindrance while for Ser-P6 both 'up' and 'down' conformations appeared to be possible and both models were constructed. Only three crystal structures for 10-mer complexes were available in the protein data bank (Table 2) , two complexes with HLA A*0201 (14) (1hhh), (44) (2clr), and one with HLA Aw68 (45) (1tmc). The peptide in 2clr has a special conformation lacking an anchor side chain in position 10 and was therefore not used for modelling. Three of many possible AVF 10-mer models were constructed based on the two remaining structures that differ in the orientation of the side chain of residue P7 ('down' in 1hhh versus 'up' in 1tmc). In these models, P1 to P4 were kept in the same conserved conformations as in the 9-mer peptides, and P9 and P10 were kept in the conserved anchor positions corresponding to position P8 and P9 in the 9-mers. One of the 10-mers was based on the structure of 1tmc, one on the structure of 1hhh and the third was also based on 1hhh but with the 'up' and 'down' conformation in P5 and P6 reversed.
Results
The bound peptide influences the recognition of HLA A*1101 molecules by allospecific mAb
To load HLA A*1101 molecules with single peptides we used an HLA A* 1101 transfected subline of the BM36.1 mutant in stabilization assays. The BM36.1 cell line carries a functionally inactive TAP2 gene which has been shown to be required for efficient loading of endogenous peptides into the groove of class I molecules (18) . When cultured at 37°C, these cells express very low levels of endogenous class I molecules reactive with the W6/32 mAb. Transfection with HLA A*1101 does not increase the reactivity with W6/32 and does not induce reactivity with the A11-specific mAb AUF5.13, HB164 and Trj14 above the level observed in untransfected cells (data not shown and Table 1 ). The recognition of A11-peptides complexes by these mAb was tested in BM36.1/ A11 cells that had been cultured overnight in medium containing 100 \iM of synthetic peptides. Fifteen A11-binding peptides were chosen for this purpose (Table 1) . Two synthetic peptides, designated IVT and AVF, correspond to previously characterized CTL target epitopes in the EBV nuclear antigen EBNA4 (23) and all peptides contain the previously defined A11-binding motif with a small hydrophobic amino acid at P2 Mean ± SE of fluorescence intensity recorded in three independent experiments performed with each peptide-mAb combination and lysine at P9 or P10 (19) . In accordance, all synthetic peptides were able to stabilize the expression of A11 at the surface of the BM36.1/A11 transfectant resulting in a significantly increased reactivity with the W6/32 mAb (Table 1) . Binding of the AUF5.13 and HB164 mAb appeared to be peptide dependent with each antibody recognizing a partially overlapping set of A11-peptide complexes. Thus, the AUF5.13 antibody recognized A11 molecules induced in the presence of the IVT, VAV, GAF, ML, IVC, SVY, SIP, AIF, ELN and SVF peptides but did not bind to molecules loaded with AVF, LLI, AVD, RVR and TIT while the HB164 antibody failed to recognize molecules loaded with AVF and LLI, and bound poorly to ML, ELN and TIT containing complexes. In line with the previously reported reactivity of the Trj14 antibody with a broad spectrum of class I A alleles (35) , all A11 complexes were recognized albeit with different efficiency, suggesting that this antibody binds to a peptide-independent determinant.
The peptide specificity of the AUF5.13 antibody was further investigated in peptide-dependent class I refolding assays performed in T2/A11 cells. This cell line was chosen because higher levels of thermolabile A11 molecules reactive with the AUF5.13 antibody can be induced by incubation at 26°C in the absence of exogenous peptides ( Fig. 1; 19 ). Peptidereceptive A11 heavy chains were induced at the cell surface by dissociating the thermolabile complexes at pH 3 in citratephosphate buffer and the molecules were then refolded by incubation at 4°C in the presence of excess 02™ anc) 10° ^M of the SIP, ELN, AVD or LLI peptides. The reactivity of the refolded A11 complexes with the W6/32 and AUF5.13 antibodies is shown in Fig. 1 . Treatment at pH 3 of T2/A11 cells which had been preincubated overnight at 26°C resulted in a 10-fold decrease of reactivity with W6/32 and virtually abolished the reactivity with AUF5.13. The binding of W6/32 was reconstituted almost completely after incubation at 4°C in the presence of peptides and f^m with no significant differences between the effect of the four peptides. Only cells incubated with the SIP and ELN peptides regained reactivity with the AUF5.13 antibody. Incubation with pyn alone resulted in partial reconstitution of W6/32 reactivity but had no effect on binding of the AUF5.13 antibody (not shown).
Solvent-exposed residues influence the recognition of A11-peptide complexes by alloantibodies and specific TCR
The interaction of A11 molecules loaded with the IVT and AVF peptides with the AUF5.13 antibody and with specific TCR was mapped by Ala scanning mutagenesis. A series of IVT and AVF analogues where each residue was sequentially substituted by Ala were tested in parallel for their ability to stabilize surface A11 expression and induce AUF5.13 reactivity in BM36.1/A11 cells, and for their capacity to sensitize A11-positive PHA blasts to lysis by IVT and AVF specific CTL. In accordance with the predicted binding motif, substitution of the C-terminal Lys residue by Ala reduced significantly the binding of both peptides (Figs 2 and 3 ) while substitutions at other positions had no effect, or, in some cases, resulted in significantly improved binding. Recognition of the IVT containing complexes by the AUF5.13 antibody was abolished by Ala substitutions at P1 and P4, while substitutions at P7 and P8 resulted in 70 and 30% reduction respectively, and substitution at P5 increased binding by 60% (Fig. 2) . The same residues appeared to be required for recognition of the IVT epitope by the majority of A11-restricted epitope-specific CTL while some of the clones were also affected by Ala substitution at P6. For the AVF epitope the residues affecting CTL recognition appear to be P3, P4, P6 and P8 (Fig. 3) .
To aid the interpretation of these results we constructed molecular models of the interaction of HLA-A*1101 with the IVT and AVF peptides. The binding of peptides to MHC molecules follows common rules for class I and class II respectively (46) . Thus in all class I molecules, Tyr7, Tyr59 and Tyr171 form a network of hydrogen bonds directly involving the peptide N-terminus while Tyr159 makes a hydrogen bond to the carbonyl oxygen of the first amino acid of peptide. At the peptide C-terminus, the terminal carboxyl group makes an ionic bond to Lys146 and a hydrogen bond to Tyr84 and Thr143 while the penultimate peptide carbonyl oxygen makes a hydrogen bond to Ne1 of Trp147. These interactions are all independent of the peptide side chain. Peptides that bind to HLA-AM101 have a Lys side chain as C-terminal anchor and this was built to make ionic interactions to Asp116 and to Asp77 as for peptides bound to HLA Aw68 (47) . The second most important peptide side chain anchor is in P2. As for HLA Aw68, a small hydrophobic residue is the preferred anchor in HLA A* 1101; Val-P2 was therefore accommodated in the corresponding hydrophobic pocket. Two models of the IVT peptide extrapolated from the canonical interactions and available crystal structures (Table 2) are shown in Fig. 4 . The peptide is oriented in the figure such that solvent exposed peptide side chains, facing away from the peptide binding cleft are pointing upwards. When the validity of the predicted models was tested by molecular dynamics only the model with the Ser-P6 side chain pointing 'down' into the groove proved to be stable. This is probably because of difficulties in finding a good binding conformation for the side chain of 51 Cr-release assays were performed at 10.1 effector-target ratio using as targets A11-positive PHA blasts that had been preincubated for 1 h with 10~9 or 10~1 0 M of the peptides during labelling. The mean ± SE of three experiments is shown. For each model the residues and atoms in the peptide are indicated in the left side column and the interacting residues in the HLA AM 101 are indicated in the right side column.
Phe-P5 when the Ser is pointing 'up'. The predicted involvement of the P6 residue in recognition by some IVT specific CTL clones suggests that this less stable conformation (Fig. 4b ) may nevertheless occur in vivo. The stable 9-mer model (Fig. 4a ) makes several main chain and side chain interactions to HLA A*1101 beside the canonical ones, including a salt bridge and several hydrogen bonds (Table 3 ). In particular there is a double hydrogen bond formed by Gin 156 to the Ser-P6 side chain and main chain 50 and a salt bridge that can be formed between the exposed Asp-P4 side chain and Arg 163 in the helix at one side of the binding cleft or, alternatively, to Arg 65 in the helix on the opposite side.
Three 10-mer models were constructed differing in their 'up' and 'down' configuration of side chains in position 3 to 51 Cr-release assays were performed at 10.1 effector target ratio using as targets A11 -positive PHA blasts that had been preincubated for 1 h with 10"" 9 or 10~1 0 M of the peptides during labelling The mean ± SE of three experiments is shown. 7 . Model 1 was 4.TT4-T, model 2 it-LTJ-and model 3 4.TTU. For model 1, based on "Itmc, the terminal Lys binding site was severely distorted after molecular dynamics and was considered an unlikely conformation. After molecular dynamics, models 2 and 3 looked rather similar with the same 'up' and 'down' pattern for the side chains (Fig. 5A-D) but with Arg-P5 and Lys-P6 side chains pointing towards opposite sides in the binding groove. In both models, the f^-carbon of the residue in P5 has an 'up' conformation but in model 3 the side chain of Arg-P5 has bent down, becoming almost buried into the groove. This form is more probable due to the concordance of the predicted TCR contact sites and the results of the Ala scanning mutagenesis (cf. Fig. 3 ). Both models place Phe-P3 in a buried conformation and are therefore somewhat contradictory to the cytotoxicity data which indicate that this residue is accessible to the TCR. Polar interactions obtained for models 2 and 3 are given in Table 3 .
The predicted binding of the IVT and AVF peptides to HLA A*1101 is shown in Fig. 6 . The mode of binding of the first three and last two residues is very similar in the two peptides, as observed in crystailographic studies of MHC-peptide complexes. After molecular dynamics all the acceptable (51) models show a shift in one of the helices forming the walls of the peptide binding site; residues 155-159 have moved in towards the peptide. In model 2 for the 10-mer the second helix is partly deformed; residues 67-72 have moved away from the floor allowing for some extra interactions to be made with the peptide. In model 3 residues 70-72 have moved away slightly to give room for the partly buried Arg-P6 side chain. From these modelling studies it may be concluded that the P1, P4, P5, P7 and P8 of IVT and P1, P4, P6, P8 and P9 of AVF are pointing away from the groove and may participate in the interaction of the complexes with specific antibodies or TCR while the remaining peptide residues are either involved in binding to specificity pockets or are pointing downwards into the cleft. Figure 7 shows the impact of the amino acid composition of the peptides listed in Table 1 on AUF5.13 recognition. Amino acid residues present in the sequence of peptides that induce recognition by the AUF5.13 mAb are listed in the upper panel while the lower panel shows the same compilation made for peptides that do not induce AUF5.13 reactivity. All amino acids are represented in the upper panel with the exception of Arg and Lys. These residues are over-represented in the lower panel, suggesting that their presence may be responsible for the lack of AUF5.13 recognition. To test this possibility, analogues of the IVT peptide containing Lys or Arg substitutions at P5 or P6 and analogues of the AVF peptides where the Arg-P5 and/or Lys-P6 were substituted with Ala were used to stabilize A11 expression in BM36.1/ A11 cells. The IVT-K5 and -R6 peptides were able to bind to A11 as efficiently as the wild type peptide as shown by W6/ 32 reactivity (Fig. 8, upper panel) . However, both substitutions abolished AUF5.13 reactivity. Substitution of either AVF-R5 or -K6 with Ala could not reconstitute AUF5.13 reactivity, while the peptide carrying Ala substitution in both positions was able to induce strong reactivity with the AUF5.13 mAb. All AVF and analogues were able to bind to HLA A*1101 as detected by their capacity to induce reactivity with the W6/ 32 mAb (Fig. 8, lower panel) . Thus, presence of residues with bulky positively charged side chains in solvent exposed positions seems to inhibit binding of the AUF5.13 antibody to A11-peptide complexes.
Bulky peptide side chains prevent binding of the AUF5.13 antibody
Discussion
The interaction of the TCR with MHC-peptide complexes is thought to involve contact sites in both the a1 and a2 helices of the MHC as well as solvent exposed residues of the peptide bound to the groove. The relative contribution of each of these to T cell recognition is not known in detail but probably differs from one TCR to the next. One issue that is frequently raised is whether the peptide induces significant changes in the conformation of the a1 and o2 helices and whether this is a critical factor in T cell recognition affecting, for example, thymic selection or TCR signalling. Recent evidence indicate that, similar to TCR, certain allospecific antibodies are able to discriminate between different MHC-peptide complexes. In some cases, the effect could be ascribed to peptidemduced conformational changes in the MHC molecule that affected determinants located outside of the combinatorial surface created by the peptide (15, 16) ; in other cases, the peptide appeared to play a direct role in antibody binding by generating steric inhibition via its solvent exposed side chains (8, 9) . In this investigation we used a large panel of HLA A*1101 binding peptide and peptide variants in an attempt to understand the nature of the recognition of A11-peptide complexes by allospecific antibodies and peptidespecific TCR. Using HLAA*1101 transfected sublines of the TAP-deficient mutants BM36.1 and T2 in peptide-induced class I stabilization assays we have demonstrated that the AUF5.13 and HB164 antibodies recognize A11 molecules in a peptidedependent fashion. Each antibody reacted with a distinct, albeit partially overlapping, set of A11 complexes induced by incubation of BM36.1/A11 cells in the presence of peptides whereas molecules expressed on cells cultured alone at 26°C reacted only marginally or not at all (Table 1 ). The thermolabile class I molecules induced under these conditions are believed to be either 'empty 1 or occupied by low-affinity peptides that are translocated to the ER independently of TAP (36, 48) . Both antibodies recognized A11 molecules expressed in T2/A11 cells incubated at 26°C in the absence of exogenous peptides (not shown). This is likely to be a peptide-dependent effect since reactivity with the AUF5.13 antibody was reconstituted by refolding the A11 heavy chains expressed in T2/A11 cells in the presence of the SIP or ELN peptides and fern (Fig. 1) , while incubation with the AVD or LLI peptides and fern or pyn alone (not shown) induced reactivity with the W6/23 antibody but had no effect on AUF5.13 binding. Since the same A11 plasmid was used for transfection of BM36.1 and T2, this discrepancy is probably explained by the expression of thermolabile molecules containing different sets of endogenous peptides. It is noteworthy that while T2 was obtained by hybridization of a T cell line CEM with a B95.8-transformed cell line of normal B cell origin, the BM36.1 mutant is derived from a B cell lymphoma and therefore expresses a different array of activation/differentiation antigens or may carry additional defects within the antigen processing/presentation pathway that could result in the production of different peptide pools.
A combination of molecular modelling and Ala scanning mutagenesis of two known CTL target epitopes was used to address the role of peptide side chains versus peptide induced class I conformational changes on the reactivity of A11 complexes with antibodies and specific TCR. Analysis of the effect of these substitutions on the capacity of Alacontaining analogues to bind to A11 molecules and stimulate antibody or T cell reactivity was used to determine the relative orientation of the peptide side chains with respect to the binding cleft. The resulting pattern has been matched to patterns derived from the known crystal structures of MHCpeptide complexes or, when compatible structures were not available, has been used to guide the search of likely conformations which were then critically examined by molecular dynamics simulations. A striking similarity was observed between the effect of Ala substitutions on the recognition of A11 molecules loaded with the IVT peptide by the AUF5.13 antibody and by specific CTL. All residues that by Ala scanning were shown to affect antibody binding are predicted to have side chains pointing away from the groove towards the solvent. The same residues were also critical for TCR recognition. Interestingly, complexes containing the IVT-A5 analogue showed a significantly improved binding to the AUF5.13 antibody but failed to trigger lysis. This does not mean that the complexes are unable to interact with the TCR. Indeed, preliminary data suggest that the IVT-A5 analogue can act as a TCR antagonist and triggers certain T cell functions including production of IL-2 and IFN-y (Levitsky etal., unpublished results). Ala substitution at P6 did not affect antibody binding in accordance with the model predicting that this residue is oriented toward the binding cleft when the peptide is held in a stable conformation. We were therefore surprised to find that, while the majority of the IVT-specific CTL clones conform to this model, about one third of the clones were affected by the substitution. There are two possible explanations for this finding. Comparison of the crystal structures of several 9-mer peptides bound to human and mouse class I molecules indicate that, when P2 and P9 provide the major anchors, different orientations are possible for residues in P6 and P7 (14) . This is probably because these residues arch away from the surface and form only weak interactions with the walls of the cleft. The Ser and Val in P6 and P7 of the IVT peptide have relatively small side chains and could therefore allow binding of the peptide in more than one conformation. Although the conformation with Ser-P6 pointing 'down' was shown to be more stable in molecular dynamics simulations, an alternative conformation with the residue pointing 'up' could be stabilized by interaction with certain TCR. Alternatively, the TCR of clone BK117 could recognize a conformation-dependent determinant of the A11-IVT complex which is lost when Ser-P6 is substituted by Ala. This possibility appears less likely given the overall conserved structure of the a-helices in crystals of the same class I molecule containing different peptides (14) and the close similarity of the Ser and Ala side chains.
In contrast to the apparent plasticity of the A11-IVT complex, models of A11 bound .to the AVF 10-mer as well as the Ala scanning mutagenesis data indicate that this complex may assume a more rigid conformation. This is probably due to the presence of two adjacent residues with bulky positive charged side chains in P5 and P6. The charge similarity suggests that these residues may assume opposite orientations. Indeed the model with Arg-P5 partly buried and Lys-P6 pointing 'up' towards the solvent, which conforms to the pattern suggested by the cytotoxicity data, was shown to yield a stable conformation. The failure to trigger lysis by the AVF-A3 analogue is somewhat intriguing. In the stable conformation suggested by model 3 the Phe-P3 points sideways towards the walls of the cleft and may not represent a TCR contact site. It is likely that the presence of Ala at this position induces significant changes in the conformation of the peptide and/or the binding cleft resulting in loss of important TCR contact sites.
The demonstration that solvent exposed residues in the IVT peptide influence the reactivity of the complexes with AUF5.13 poses the question of the role of peptide side chains in antibody binding. Analysis of the sequence of peptides that are able to induce reactivity did not reveal a conserved motif except perhaps for a weak correlation with the presence of a residue with negatively charged side chains in P4 or P5 that was observed in six of ten recognized peptides. This could mean that there is no direct interaction between the antibody and the peptide side chains. However, it is also possible that the affinity of antibody binding is too high to demonstrate the type of absolute all-or-nothing effect which characterizes TCR reactivity. This high affinity may result in the capacity to accommodate several different residues at each position of the peptide as long as the overall conformation and charge of the combinatorial surface is maintained. In support of this possibility all peptides that failed to induce AUF5.13 reactivity were shown to carry residues with bulky positively charged side chain in solvent exposed positions. The capacity of these residues to sterically hinder antibody binding was confirmed by the loss of recognition of IVT analogues carrying Lys in P5 or Arg in P6. It is noteworthy that the bulky side chain of the Arg-P6 analogue cannot be accommodated in the D pocket as predicted for the original Ser and would therefore assume an upwards conformation. As previously observed with other IVT specific effectors (19) , this analogue is also not recognized by the BK112 clone (not shown) suggesting that the same type of steric hindrance could also prevent the interaction with this TCR. The positively charged side chains of P5 and P6 are likely to be responsible for the failure of the AUF5.13 antibody to recognize complexes of A11 with the AVF peptide. The inability to recognize the AVF-A6 analogue is probably due to reorientation of the Arg-P5 residue upon elimination of the repulsive forces generated by the positively charged Lys in P6. Thus, it is not surprising that reconstituting of AUF5.13 reactivity required substitution of both the positively charged residues.
In summary, the use of molecular modelling has allowed us to assess the role of peptide side chains in determining the mode of interaction of allospecific antibodies and peptide specific TCR with HLA A*1101 complexes for which a crystal structure has not been reported. Our results indicate that solvent-exposed side chains play a critical role in both interactions, suggesting that similar binding surfaces may be recognized. It should be stressed that only few reports have addressed the interaction of TCR with MHC complexes in terms of binding and most of the available information is based on the triggering of post-binding events such as calcium influx, cytotoxic activity or lymphokine production. Recent studies demonstrate that TCR can interact with a wide range of similar peptides. This interaction often results in differential intracellular signalling and the pattern of triggered events is determined by the structure of the particular peptide analogue. The similarity between antibodies and TCR is even more pronounced when antibodies are compared with allospecific T cells. These appear to express TCR of relatively high affinity (49) and often recognize MHC complexes assembled with several structurally similar peptides (50) . An interesting aspect of the analysis presented in this paper is the observation that, while certain complexes appear to form a relatively rigid structure, other complexes may assume more than one conformation that is available for recognition by specific TCR.
